MDS & Myeloproliferative Neoplasms

MDS & Myeloproliferative Neoplasms

A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.

Rusfertide Helps Patients With Polycythemia Vera Avoid Phlebotomy

Patients with polycythemia vera (PV) who received rusfertide were able to avoid therapeutic phlebotomy for seven months, even among those with high-risk disease, according...
On location

Evaluating Enasidenib, With or Without Azacitidine, in Patients with IDH2-Mutated MDS

Enasidenib was had a tolerable safety profile and showed promising clinical activity in patients with IDH2-mutated, high-risk myelodysplastic syndromes (MDS), according to results from...
On location

PATHFINDER: Avapritinib Induces Rapid Responses in Advanced Systemic Mastocytosis

Three-quarters of patients with advanced systemic mastocytosis (SM) responded to treatment with the oral KIT D816V inhibitor avapritinib, according to interim results from the...

Four of a Kind?

Soon, there may be as many as four JAK inhibitors available for patients with myelofibrosis. For many of his patients with myelofibrosis, ruxolitinib has been...

How Do Patients With Myeloproliferative Neoplasms Fare After COVID-19 Infection?

Two analyses from the MPN-COVID study from a group of researchers led by Tiziano Barbui, MD, of the United Hospitals of Bergamo in Italy,...

Is Pretransplant Disease Reduction Necessary in MDS and AML?

For patients with myelodysplastic syndromes (MDS) or low-blast secondary acute myeloid leukemia (AML), allogeneic hematopoietic cell transplantation (AHCT) is the only potentially curative treatment...

HLA-Haploidentical Relative and Matched Unrelated Donor Transplant Lead to Similar Survival Outcomes in MDS

Transplantation with an HLA-haploidentical relative donor is associated with similar two-year survival rates compared with transplantation with a matched unrelated donor in patients with...
WIB_icon

Leukemia Antigen–Specific Donor-Derived T Cells Enhance Graft-Versus-Leukemia Effects in Post-Transplant AML/MDS

For patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) whose disease relapses following a hematopoietic cell transplantation (HCT), unselected donor lymphocytes typically...
On location

Venetoclax and Azacitidine Combination Associated With Durable Responses in Higher-Risk MDS

More than three-quarters of patients with higher-risk, treatment-naïve myelodysplastic syndromes (MDS) responded to the combination of venetoclax plus azacitidine, according to study results presented...
On location

Loss of STK11/LKB1 Drives Progression to Leukemia in Myeloproliferative Neoplasms

Results from a CRISPR/Cas9 screening study suggest that loss of STK11 promotes progression to leukemia in patients with myeloproliferative neoplasms (MPNs), according to findings...
Advertisement

Current Issue

June 2021 Volume 7 Issue 7

This issue reviews the management and prevention of peripheral neuropathy, early successes of SCD screening programs in sub-Saharan Africa, and more.

Block title